The QualityStocks Daily Thursday, October 14th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(PLLWF) $0.9991 +66.52%

MarketClub Analysis(GRVI) $6.9800 +39.32%

NetworkNewsWire(HLTT) $0.4300 +26.47%

The QualityStocks Daily Stock List

Franklin Wireless Corporation (FKWL)

MarketBeat, QualityStocks, MarketClub Analysis, OTC Picks, SmallCapVoice, Marketbeat.com, Greenbackers and FeedBlitz reported earlier on Franklin Wireless Corporation (FKWL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Franklin Wireless Corporation (NASDAQ: FKWL) is engaged in the provision of intelligent wireless solutions.

The firm has its headquarters in San Diego, California and was incorporated in 1981. The firm serves consumers around the globe.

The company operates thoroughly its subsidiary, Franklin Technology Inc., an R&D firm that is engaged in the provision of design and development services for wireless products. It indirectly markets its products through distributors and strategic partners and directly markets its products to wireless operators located mainly in Asia, South America, the Caribbean, North America, the Middle East and Africa.

The enterprise designs software and hardware enabling machine-to-machine applications and the Internet of Things. These solutions include gateways, modems and embedded modules that have been built to deliver applications based on 4th generation and 5th generation technology (4G/5G). It also provides Internet of Things server applications and platforms, 5G/4G LTE wireless broadband products and IoT connected devices and tracking devices. This is in addition to offering mobile technologies which include mobile device management solutions, 5G/4G customer premises equipment and 5G/4G mobile hotspots. The enterprise’s products have been designed to solve wireless connectivity issues in various markets, including vehicle diagnostics, telematics, smart grid, fleet management, oil and gas exploration, home security, digital signage and video surveillance.

The firm plans to launch a new sub-6 5G mobile hotspot in partnership with a diversified telecommunications and technology services firm known as C Spire. This move will bring in additional revenues to both firms and extend the firm’s consumer reach, which may have a positive influence on investments and growth.

Franklin Wireless Corporation (FKWL), closed Thursday's trading session at $6.06, up 1.6779%, on 87,772 volume with 482 trades. The average volume for the last 3 months is 87,772 and the stock's 52-week low/high is $5.25/$28.14.

United Insurance Holdings (UIHC)

Zacks, MarketBeat, StreetAuthority Daily, StreetInsider, TopStockAnalysts, The Street, RedChip, Marketbeat.com, InvestorPlace, Dividend Opportunities, The Best Newsletters, Real Pennies, Market FN, Daily Trade Alert and Barchart reported earlier on United Insurance Holdings (UIHC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

United Insurance Holdings Corp. (NASDAQ: UIHC) (FRA: 0UI) is a property and casualty insurance holding firm that services, writes and sources casualty insurance policies and commercial and residential personal property.

The firm has its headquarters in St. Petersburg, Florida and was incorporated in 1999. The firm primarily serves clients in the United States.

The company operates through its subsidiaries, which include United Property & Casualty Insurance Company, its insurance subsidiary. Its other subsidiaries include UPC Re, which offers a portion of the reinsurance protection brought by its insurance affiliate Skyway Claims Services LLC, which offers services to its insurance affiliate, and United Insurance Management L.C., which operates as the managing general agent and manages almost all aspects of the insurance subsidiary’s business.

The enterprise provides dwelling fire policies and liability, content and structure coverage for condominium unit owners, renters and single-family homeowners. It also provides cyber security and inland flood insurance, and identity theft, equipment breakdown and flood policies. In addition to this, it offers commercial multi-peril property insurance for residential condo associations. The enterprise distributes and markets its products via a network of independent agencies in Texas, South Carolina, Rhode Island, North Carolina, New York, New Jersey, Massachusetts, Louisiana, Hawaii, Georgia, Florida and Connecticut.

The firm is focused on achieving strong underwriting profit and its transition plan, which will facilitate an increase in reinsurance spend and involves increasing quota share of protection, which will decrease volatility and de-stress capital in both its personal line and commercial businesses. This may help bring in more investors into the firm.

United Insurance Holdings (UIHC), closed Thursday's trading session at $4.18, off by 1.182%, on 140,762 volume with 1,540 trades. The average volume for the last 3 months is 140,583 and the stock's 52-week low/high is $2.76/$8.16.

Aravive Inc. (ARAV)

MarketBeat, TradersPro, StockMarketWatch, MarketClub Analysis, TopPennyStockMovers, StreetInsider and BUYINS.NET reported earlier on Aravive Inc. (ARAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aravive Inc. (NASDAQ: ARAV) is a clinical-stage biopharmaceutical firm that is focused on the development of treatments for life-threatening ailments with a focus on hematologic malignancies and various cancers.

The firm has its headquarters in Houston, Texas and was incorporated in 2008, on December 10th. Prior to its name change in October 2018, the firm was known as Versartis Inc. It mainly serves consumers in the United States.

The company is party to a license agreement with 3D Medicines Inc. which entails the development of products that contain its AVB-500 product as the single drug substance for the treatment of human oncological ailments in Macau, Hong Kong, Taiwan and mainland China. It is also party to a strategic collaboration agreement with WuXi Biologics which entails the development of new high-affinity bispecific antibodies that target fibrosis and cancer.

The enterprise’s product portfolio comprises of a soluble Fc-fusion protein dubbed AVB-S6 which blocks the activation of the GAS6-AXL signaling pathway. It also produces a decoy protein dubbed AVB-500 which targets the GAS6-AXL pathway. The protein is currently in a phase 2b/3 clinical trial evaluating its effectiveness in treating platinum-resistant recurrent ovarian cancer, as well as non-small-cell lung cancers, urothelial, pancreatic cancer, uterine, HER negative breast cancers and clear renal cell carcinoma.

The company is focused on advancing its AVB-500 formulation as a treatment for pancreatic adenocarcinoma. The success and approval of this formulation for this particular indication would meet significantly unmet medical needs for patients, which will not only benefit them but also bring in more investors into the firm, which would boost the company’s growth.

Aravive Inc. (ARAV), closed Thursday's trading session at $3.83, up 1.0554%, on 61,289 volume with 409 trades. The average volume for the last 3 months is 54,058 and the stock's 52-week low/high is $3.47/$9.95.

Itau Unibanco Holding SA (ITUB)

MarketClub Analysis, Schaeffer's, MarketBeat, InvestorPlace, StocksEarning, Marketbeat.com, The Street, Zacks, Louis Navellier, TradersPro, Daily Trade Alert, Investor Guide, Investiv, INO Market Report, Navellier Growth, Market Intelligence Center Alert, Trades Of The Day, Trading Markets, StreetAuthority Daily, SmarTrend Newsletters, ChartAdvisor, Wall Street Greek, Daily Wealth, Direction Alerts, Dynamic Wealth Report, Uncommon Wisdom, Investopedia, Money and Markets, BUYINS.NET, SmallCapVoice, TopStockAnalysts, The Trading Report, StreetInsider, Stock Gumshoe, StockMarketWatch and TradingMarkets reported earlier on Itau Unibanco Holding SA (ITUB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Itau Unibanco Holding S.A. (NYSE: ITUB) (FRA: BVXB) is focused on the provision of financial services and products internationally and in Brazil.

The firm has its headquarters in São Paulo, Brazil and was incorporated in 1943, on September 9th. Prior to its name change in April 2009, the firm was known as Itau Unibanco Multiplo S.A. It was formed as a result of a merger between Banco Itau and Unibanco. The firm serves consumers around the globe.

The company operates through the wholesale banking, retail banking and the activities with the market and corporation segments. The activities segment is involved in results arising from the net balance of debts and tax credits, subordinated debt surplus and capital surplus. The wholesale segment provides investment and corporate banking activities, which include its middle-market banking business. On the other hand, the retail segment includes a variety of credit services and products for small companies and individuals, as well as capitalization, pension plan, insurance and asset management products and credit cards.

The enterprise provides credit cards, loans, foreign exchange and leasing services, financing and investment services, real estate lending services and investment banking services. It serves microenterprises, high income clients, legal entities, individuals, non-account and account holders and retail customers.

The firm recently released its latest financial results for the 2021 financial year which show increases in revenue as well as improvements in client acquisition. It is now focused on changing its consumer experience by redefining the value proposition in its retail segment and increasing sales through digital channels.

Itau Unibanco Holding SA (ITUB), closed Thursday's trading session at $4.32, off by 1.1442%, on 20,045,391 volume with 22,890 trades. The average volume for the last 3 months is 19.926M and the stock's 52-week low/high is $3.96/$6.76.

Voyager Therapeutics (VYGR)

InvestorPlace, TraderPower, MarketBeat, StockMarketWatch, StreetInsider, Kiplinger Today, BUYINS.NET, The Online Investor, Daily Trade Alert, Barchart, Trades Of The Day, Schaeffer's, MarketClub Analysis, Trading Concepts and StreetAuthority Daily reported earlier on Voyager Therapeutics (VYGR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Voyager Therapeutics Inc. (NASDAQ: VYGR) (FRA: VT6) is a clinical-stage gene therapy firm that is engaged in the development of treatments for serious neurological illnesses.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in June 2013 by Phillip Zamore, Krystof Bankiewicz, Mark A. Kay and Guang Ping Gao. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm has two companies in its corporate family.

The company is party to a license and collaboration agreement with Neurocrine Biosciences Inc. which entails researching, developing and commercializing adeno-associated virus-based gene therapy products. It is also party to a collaboration with Fujifilm Diosynth Biotechnologies and Thermo Fisher Scientific, which aid in the development of its gene therapy programs; and strategic collaboration agreements with ClearPoint Neuro Inc. and the University of Massachusetts.

The enterprise’s product portfolio is made up of its Tau program for the treatment of frontotemporal dementia, progressive supranuclear palsy and Alzheimer’s disease; VY-FXN01 which has been developed to treat Friedreich’s ataxia; and VY-HTT01 which has been developed to treat Huntington’s disease. It also develops VY-SOD102 which has been developed to treat amyotrophic lateral sclerosis. In addition to this, the enterprise also develops VY-AADC, which is in a phase I clinical trial evaluating its effectiveness in treating Parkinson’s disease.

The company, which has a rich pre-clinical pipeline of second-generation and new programs, recently entered into an agreement with Pfizer. This agreement is bound to bring in more investments as well as growth opportunities into the company.

Voyager Therapeutics (VYGR), closed Thursday's trading session at $4.4, off by 2.8698%, on 3,240,730 volume with 12,800 trades. The average volume for the last 3 months is 3.198M and the stock's 52-week low/high is $2.46/$12.65.

ReelTime Rentals, Inc. (RLTR)

QualityStocks, PennyStocks24, Real Pennies and Juicy Penny Stocks reported earlier on ReelTime Rentals, Inc. (RLTR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ReelTime Rentals, Inc. (d/b/a ReelTime VR, ReelTime Media Group) is a multimedia publishing business. The Company engages in helping individuals that have been thrust into the public eye to monetize their exposure and control the portrayal of their story. In addition, it develops, produces, and distributes Virtual Reality (VR) Content and technologies under the brand ReelTime VR. ReelTime is headquartered in Seattle, Washington and lists on the OTC Markets.

ReelTime has end to end production, editing, and distribution capabilities for internal and external projects. At present, the Company produces three ongoing series for the Samsung Gear VR platform, VeeR TV, Oculus. It distributes them over manifold VR delivery sites.

Regarding Partnerships, ReelTime partners with other top VR distributors, content producers, and technology providers. Furthermore, concerning its Services, the Company offers Consulting, Production, Monetization, VR Set Design, VR Media Campaigns, as well as VR Content Production.

Pertaining to VR Set Design, ReelTime has a totally-dressed virtual set in its studio facilities. It can create any look one wants for their Virtual Reality show. Also, it can provide traditional virtual set backdrops.

Concerning VR Content Production, ReelTime has a team of editors and other pre/post-production professionals available for all elements of producing VR content. This is from the initial design concepts, to pixel-perfect deliverables.

ReelTime VR announced recently that it became the first to utilize a proprietary technology developed by the Company that allows it to film in full 360 x 360 Virtual Reality formats and simultaneously film in formats compatible with traditional Television platforms. This will allow ReelTime VRs shows the Company produces to not only be available on the rapidly growing premium VR sites it is currently available on, but it will additionally be available for distribution over mainstream Network Television formats and worldwide.

ReelTime has received patent-pending status from the United States Patent and Trademark Office (USPTO) for its non-provisional patent application encompassing apparatus and method claims for technology involving simultaneous capturing of 360 X 360-degree Spherical Panorama Images and Video. The technology will enable any cell phone or other camera to promptly capture 360 X 360 Virtual Reality Video or pictures without any need for stitching.

The VR content is compatible with and can be shared through 360 capable social sites in real time, and on any professional VR platform such as Oculas, Gear VR, Veer VR, Playstation VR, Littlstar, and the HTC Vive.

ReelTime will start using this inventive technology in its production of its award-winning Virtual Reality travel series “In Front of View”. The series commenced filming its second season in Thailand in July. It is shot in English and in Thai. Moreover, ReelTime VR is entertaining licensing agreements with select other VR, film, and TV producers to allow them to also gain a competitive advantage.

ReelTime Rentals, Inc. (RLTR), closed Thursday's trading session at $0.114, up 24.5902%, on 802,007 volume with 107 trades. The average volume for the last 3 months is 802,007 and the stock's 52-week low/high is $0.0502/$1.03.

DATATRAK International, Inc. (DTRK)

QualityStocks, MarketBeat and StreetInsider reported earlier on DATATRAK International, Inc. (DTRK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DATATRAK International, Inc. is a global Software-as-a-Service (SaaS) provider and innovation leader of cloud-based technologies for the life sciences industry. The Company delivers unified eClinical solutions and related services for the clinical trials industry. DATATRAK delivers a complete portfolio of software products designed to hasten the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. Founded in 1991, DATATRAK International is based in Cleveland, Ohio, and College Station, Texas. The Company lists on the OTC Markets.

DATATRAK International built its multi-component, complete solution on a single, unified platform. The DATATRAK software solution, deployed internationally through an ASP or Enterprise Transfer offering, supports Pre-clinical, Phase I – Phase IV drug, device and diagnostic studies in many languages. The DATATRAK Enterprise Cloud includes Business Intelligence, CTMS, Trial Design, Electronic Data Capture (EDC), Medical Coding, Risk-Based Monitoring, ECG Data Capture, Image Data Capture, Endpoint Adjudication, Randomization, Clinical Supply Inventory, eConsent, ePRO, and eCOA.

The Company’s vision moving forward is to continue to build and own a multilingual and multi-tenant enterprise platform with unified access to clinical applications, database, as well as workflows. Additionally, its emphasis is to ensure scalable and operational efficiency. This is while eliminating the need for back-end integration that is the cause of common friction points.

DATATRAK International’s commitment is to enabling workgroup teams with role-based access to version-controlled file management, calendar events, tasks and contacts, all built within their eClinical applications. This includes EDC, CTMS, reporting, data analytics, and business intelligence.

DATATRAK International, Inc. (DTRK), closed Thursday's trading session at $11.75, up 23.5542%, on 489 volume with 5 trades. The average volume for the last 3 months is 489 and the stock's 52-week low/high is $3.50/$30.00.

Viper Networks (VPER)

SmallCapVoice, Triple Crown Stocks, Microcap Money, Greenbackers, PennyStocks24, OTCPicks, Penny Stocks VIP, Bull in Advantage, MadPennyStocks, HotOTC, CoolPennyStocks, PennyStockVille, Penny Stock Circle, Penny Stock Pros, Penny Stock Rumble, BullRally, 1-2-3 Stock Alerts, PennyStockClub, MajorPennyStocks, StockEgg, QualityStocks, SizzlingStockPicks, WINNINGOTC, Wall Street Beauties, TryBestPennyStocks.biz, SmallCapAllStars, StockRich, StockMarketQuote.us, PennyInvest, StockRunway, The Stock Scout, The Cervelle Group, InvestorPlace, Information Solutions Group, Editor Microcaps, Daily Stock Motion, FatCat Stocks, Orbit Stocks, PennyTrader Publisher, Stockgoodies, Penny Pick Insider, Stock Traders Chat, Penny Stock Rally, SMS Penny Picks, SmallCap Sentinel, WiseAlerts, PennyStockRumors.net and Nebula Stocks reported earlier on Viper Networks (VPER), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Viper Networks Inc. (OTC: VPER) is an India based firm that is engaged in the distribution and manufacture of LED lighting products. These products offer easy lighting solutions for warehousing facilities, parking lots and metropolitan areas such as highways and streets.

The firm, which has its headquarters in Troy, Michigan in America, gets the majority of its revenue from selling LED products. The company was founded in 1983 by Zachary Wild and Gregg Mojica. In addition to this, the company, which is a part of the telecommunications services industry, provides intelligent lighting solutions with wireless, sensor and camera technologies.

There are 3 firms under Viper Networks Inc. which the firm develops and manages by helping navigate difficult markets, identifying new opportunities and assisting in marketing and sales. The company’s services include VOIP network design and implementation, microwave and radio frequency site survey and planning, installation of telecommunication systems and network and drive test optimization.

Viper Networks Inc. also offers telecommunication engineering services for network expansion and planning and managed services of different telecom vendors and networks to telecom service providers. Apart from having investments in emerging technologies such as internet protocol based tech, wireless and software services, the company also offers multi-vendor managed solutions and services to telecom service providers of different networks in Africa and the Middle East.

As of 2021, the firm reported that it would be upgrading their Apollo Smart Light products using 5G technology. The firm’s Apollo Smart Lights create new sources of revenue for both the public and private sectors while cutting costs and decreasing the environmental footprint. This may bring good tidings for both the company’s stocks and its shareholders in the rapidly growing industry.

Viper Networks (VPER), closed Thursday's trading session at $0.0067, up 48.8889%, on 319,681,942 volume with 2,219 trades. The average volume for the last 3 months is 319.682M and the stock's 52-week low/high is $0.000001/$0.0731.

HAVN Life Sciences, Inc. (HAVLF)

QualityStocks and InvestorPlace reported earlier on HAVN Life Sciences, Inc. (HAVLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HAVN Life Sciences, Inc. is a biotechnology company pursuing standardized extraction of psychoactive compound. It is also pursuing the development of natural healthcare products and unique mental health treatment to support brain health and enhance the capabilities of the mind. Fundamentally, HAVN is formulating the next generation of medicine using psychedelic compounds. Established in 2020, HAVN Life Sciences is based in Vancouver, British Columbia. The Company lists on the OTC Markets.

HAVN Life Sciences supports research for microdosing therapies in treating mental health disorders using psychedelics. The Company works with Veterans and thought leaders in the military. It is developing inventive formulations to support clinical trials addressing Post-Traumatic Stress Disorder (PTSD) recovery and other trauma related disorders.

HAVN’s emphasis is on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, as well as the development of natural health care products from novel compounds. HAVN Labs is licensed lab dedicated to the advancement and formulation of regulated and novel psychoactive compounds.

HAVN Life Sciences recently announced it signed a Memorandum of Agreement (MOA) with the international veterans organization, Heroic Hearts Project (Heroic Hearts). As part of the agreement, HAVN Life will supply products for future U.S. and Canadian studies, upon approval of its Licensed Dealer application. The Company’s scientists will provide support for Heroic Heart's present studies and aid in the development of research protocols.

Furthermore, this collaboration will explore the use of mental health and pharmacology management platforms to collect baseline and usage data from veterans. HAVN Life is also providing funding to launch a Heroic Hearts division in Canada, to help expand support to Canadian Veterans. Heroic Hearts is a registered 501(c)(3) non profit organization founded in the U.S. It connects military veterans grappling with mental trauma, to psychedelic therapy options. This includes ayahuasca, psilocybin, as well as ketamine.

HAVN Life Sciences previously announced the first preclinical study to center on the effects of psilocybin on the immune system, in partnership with Dr. Geoffrey Bove, Dr. David Mokler and Susan Chapelle, eMBA. The Company's science division, HAVN Research, is undertaking a study to ascertain if a single dose of psilocybin extract can impact the body's inflammatory response and regulate the human immune system.

HAVN Life Sciences, Inc. (HAVLF), closed Thursday's trading session at $0.22, up 26.5095%, on 307,165 volume with 83 trades. The average volume for the last 3 months is 307,165 and the stock's 52-week low/high is $0.151/$1.25.

R-Three Technologies, Inc. (RRRT)

We reported earlier on R-Three Technologies, Inc. (RRRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

R-Three Technologies, Inc. produces an interlocking asphalt brick by recycling asphalt shingles in their entirety. It is the only manufacturer of interlocking products engineered from l00 percent recycled material. Its products are used in varied commercial applications. These applications include driveways, patios, pool decks, courtyards, sidewalks, and medians. Founded in 2007, R-Three Technologies is based in Caledon, Ontario. The Company lists on the OTC Markets.

R-Three Technologies has developed technologies designed to recycle used and off-specification asphalt shingles rather than have them deposited in landfills. Concerning its process, the nails are also recovered and sold for scrap. The design of the bricks are to compete favorably with asphalt and concrete in a variety of commercial applications.

The Company’s product can be pressed into larger sized segments and installed as sound barrier panels, cushioned factory or stable floors and manifold other uses. Its products are lighter and denser than asphalt. In addition, the product is easier to install than concrete. A typical 6″ x 12″ x 2″ brick weighs about six pounds. This is half the weight of a similar concrete brick. The lighter weight reduces transportation and handling costs.

The bricks are non-porous and therefore will repel water and oil allowing them to retain their character and appearance. R-Three Technologies states that it will have the ability to produce product in almost any size, shape, and color. Additional end products are being investigated and considered.

R-Three Technologies previously announced that its Board of Directors appointed Mr. James L. Robinson as President, Chief Operating Officer, and member of the Board of Directors. Mr. Robinson is an experienced strategist, with a strong understanding of building high-value consumer brands with considerable annual revenue. Mr. Robinson brings substantial expertise to this role. He is one of the Founders and President of Hip Hop Beverage Corporation, whose product lines included Pit Bull Energy Drinks & Energy Bars.

R-Three Technologies, Inc. (RRRT), closed Thursday's trading session at $0.49, up 28.9474%, on 183,523 volume with 80 trades. The average volume for the last 3 months is 183,523 and the stock's 52-week low/high is $0.05/$0.855.

Polarean Imaging Ltd. (PLLWF)

We reported earlier on Polarean Imaging Ltd. (PLLWF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Polarean Imaging Ltd. designs and manufactures equipment for the production of hyperpolarized xenon or helium gas. The Company’s team has a combined 50 years of experience in the design, development, production and service of hyperpolarized equipment. A clinical-stage enterprise, Polarean Imaging’s core technology is a drug-device combination product that enables the visualisation of hyperpolarised 129Xe (HPX) using MRI technology to help diagnose lung disease earlier, identify the kind of intervention likely to benefit a patient, and to monitor the efficacy of treatment. Polarean Imaging is based in the Research Triangle Park area of North Carolina (Durham).

The Company launched in January 2012 after securing all of GE Healthcare’s assets in the field of hyperpolarized gas MRI. This includes the exclusive rights to roughly 30 patent families. At present, Polarean Imaging’s technology is for investigational use only. The Company is pursuing regulatory approval for clinical use. In addition, it sells its hyperpolarizers and related equipment to academic research institutions around the world.

Polarean Imaging systems are installed at academic research institutions internationally, including the United States, Canada, the United Kingdom, Germany, and Sweden. Further to providing academic researchers with this equipment and support, the Company. offers access to the intellectual property (IP) that provides freedom-to-operate in this technology area.

Hyperpolarization of 129Xe is accomplished through placing a non-radioactive isotope of the Xenon source gas into a beam of polarized laser light in the presence of very small amounts of an alkali metal. The result is Xenon, whose nuclear magnetic spin is highly aligned, but not chemically or biologically different than un-polarized Xenon, a harmless inert gas.

Upon the Xenon being hyperpolarized, it can be dispensed in a plastic bag, the amount of polarized gas is verified and then it is administered to the subject already lying down inside the MRI scanner. The patient inhales a small quantity (a few hundred ml) of the gas and undergoes a MRI scan. The MRI scan is usually completed within a 10-20 second breath hold.

Polarean Imaging recently announced positive top-line results from two pivotal Phase III clinical trials of its drug-device combination that uses hyperpolarized 129Xenon gas MRI to visualize and quantify regional lung function. The drug, 129Xenon, when polarized in the Company’s proprietary system, permits functional, regional and quantitative imaging of the lungs using MRI, without the use of ionizing radiation.

Mr. Richard Hullihen, Chief Executive Officer of Polarean Imaging, said, “The positive results of these clinical trials validate our belief that Polarean’s technology allows clinicians to visualize aspects of lung function, which have never before been visible by MRI, both safely and quantitatively… Given the limitations of existing methods to diagnose and monitor lung disease, we see a significant unmet need for non-invasive, quantitative and cost-effective image-based diagnosis technology without exposing patients to ionizing radiation. We believe that our technology has the potential to overcome these limitations and we look forward to using data from the clinical trials to support our New Drug Application.”

Polarean Imaging Ltd. (PLLWF), closed Thursday's trading session at $0.9991, up 66.5167%, on 117,733 volume with 1 trade. The average volume for the last 3 months is 117,733 and the stock's 52-week low/high is $0.565/$1.50.

Yatra Online, Inc. (YTRA)

MarketBeat, StreetInsider, StockMarketWatch, Zacks, Schaeffer's, MarketClub Analysis and Daily Market Beat reported earlier on Yatra Online, Inc. (YTRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Price Target Raised; Estimates Raised

Yatra Online (NASDAQ: YTRA) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “Raise Price Target To $4.00 (From $3.50); We Think 1Q:F22 Was A Trough Quarter; Project Sequential Revenue Improvement; Solid Financials, In Our View; Maintain Moderate Risk Rating.”

Click here to access the full report.

Yatra Online is the parent company of Yatra Online Pvt. Ltd., which is based in Gurugram, India, and is India's leading corporate travel services provider with over 700+ corporate customers and one of India's leading online travel companies and operates the website www.Yatra.com. The company provides information, pricing, availability and booking facility for domestic and international air travel, domestic and international hotel bookings, holiday packages, buses, trains, in-city activities, inter-city and point-to-point cabs, homestays and cruises. As a leading platform of accommodation options, Yatra provides real-time bookings for more than 94,000 hotels in India and over 2,000,000 hotels around the world. The company has also further expanded its digital offerings in non-travel categories such as freight forwarding services.

Yatra Online, Inc. (YTRA), closed Thursday's trading session at $2, up 0.502513%, on 62,057 volume with 257 trades. The average volume for the last 3 months is 62,057 and the stock's 52-week low/high is $0.79/$2.94.

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform. SRAX recently announced the merger between its subsidiary, Force Protection Video Equipment Corp. (“FPVD”), also known as BIGtoken, and BritePool, an identity resolution and verification service for advertisers and publishers. BritePool provides precise, frequency-controlled identity targeting without third-party cookies, while BIGtoken serves as a data marketplace that encourages users to share information in exchange for incentives. “The combined entity will aim to provide the next evolution of privacy focused solutions, with benefits for consumers and advertisers,” reads a recent article. “SRAX expects the transaction, which is awaiting regulatory approval, to benefit the company’s shareholders.” To view the full article, visit https://ibn.fm/k4nIp

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $6.03, up 6.3492%, on 282,027 volume with 1,732 trades. The average volume for the last 3 months is 282,027 and the stock's 52-week low/high is $2.06/$7.29.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

NetworkNewsWire Editorial Coverage: A top trend driving change in the food and beverage space is consumers’ growing demand for products that support health and wellness. Research from Archer Daniels Midland (“ADM”) indicates that 77% of consumers want to do more to stay healthy in the future, and savvy companies are working quickly to give customers what they want. With consumers choosing healthier options for both food and drink, the sales of alkaline waters, those with a pH between 7.0 and 10.0, are jumping. Only a few years ago, retail sales for alkaline waters were under $95 million. Today, Beverage Marketing Corp. projects retail sales in the category to reach $1.3 billion by 2023, representing 20% of the entire value-added water category. Several factors are contributing to the forecasted 42.6% compound annual growth rate, a CAGR that The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), the largest independent alkaline water company in the United States, is ideally positioned to benefit from. 

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Thursday's trading session at $1.61, up 1.2579%, on 1,002,191 volume with 3,488 trades. The average volume for the last 3 months is 1.002M and the stock's 52-week low/high is $0.93/$2.35.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has finalized the acquisition of BayMedica Inc., a private company based in the U.S. specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. INM had announced the acquisition earlier. According to the announcement, the acquisition provides capabilities and resources to accelerate InMed’s commercial initiatives, including the development and unveiling of several new cannabinoids products in the consumer health and wellness sector. The combined technologies include synthetic biology, chemical synthesis and IntegraSyn(TM), a patented enzymatic biotransformation. The company noted that, with the acquisition, it will become a market leader in the manufacturing of rare cannabinoids.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $1.55, up 5.4422%, on 1,671,831 volume with 3,793 trades. The average volume for the last 3 months is 1.647M and the stock's 52-week low/high is $1.43/$6.42.

Recent News

Moon Equity Holdings Corp. (OTC: MONI)

The QualityStocks Daily Newsletter would like to spotlight Moon Equity Holdings Corp. (MONI).

Moon Equity Holdings (OTC: MONI), a pioneer within the global fintech sector, is looking to capitalize on the burgeoning interest within the cryptocurrency and blockchain space. This comes amid the rapid emergence of cryptocurrencies and blockchain technology as the latest frontier within the fintech sector, with online financial solutions enabling users to quickly and efficiently mine and trade digital coins. An investment company focused on acquisitions in real estate, precious metals and cryptocurrency, MONI is working on a crypto component currently under development, alongside two proprietary applications designed to revolutionize how people gift and purchase cryptocurrency. A recent article reads, “Through its venture into the digital currency space, Moon Equity Holdings expects to enhance customer experience and create a loyal following, generating repeat business.” To view the full article, visit https://ccw.fm/P0F2b

Moon Equity Holdings Corp. (OTC: MONI) is an investment company that focuses on acquisitions in the fintech, crypto, precious metals and real estate sectors. The company’s goal is to enhance the profitability of these acquired companies, which in turn will increase shareholder value. Moon Equity Holdings’ philosophy is to provide its shareholders with a well-diversified acquisition portfolio focused on income-generating strategies that produce long term gains.

The company has been working on a crypto component in development, along with two trademarked products that will revolutionize how people gift and purchase cryptocurrency. With this, Moon Equity Holdings will use decentralized technology to enhance customer experience. First-rate service is the cornerstone of Moon Equity Holdings’ success. The company’s focus on best-in-class customer service is expected to create a loyal brand following and generate repeat business.

Business Operations

Moon Equity Holdings Corp. acquired Royal Costino LLC as a wholly owned subsidiary for its newly created Mining Division. Its primary business is processing, buying, selling and exporting precious metals. This acquisition completes the first step of the two planned mining acquisitions for this year. The acquisition is expected to significantly enhance revenue for the company, generating an estimated $2 million per month in additional income. Royal Costino’s facility has been in operation since 2013, and its team has more than 30 years of experience in this field.

Management Team

Moon Equity Holdings Corp. has assembled a highly skilled and experienced management team.

Alison Galardi is the CEO of Moon Equity Holdings Corp. Before joining the company, she gained more than 20 years of experience at Fortune 100 financial services companies, including Spear Leeds & Kellogg, TIAA-CREF and Citigroup, where she held positions in global banking, institutional sales, trading and investor relations.

Anthony Cappaze is head of Moon Equity Holdings’ Mining Division with more than 30 years of mining experience. He was founder and CEO of Royal Sovereign Costino prior to its acquisition by Moon Equity Holdings Corp.

Advisory Board

Sue Ferrari is a Senior Industry Principal that has over 20 years of experience in innovation, insights and analytics across technology, financial services and media, including VP, Bank of NY Mellon and ADP.

Maureen Vizvary worked at Microsoft, HP and Xerox launching innovative products and developing marketing campaigns that rebrand entire organizations. During her tenure at Microsoft, she served on the advisory team restructuring Microsoft’s mid-market sales division and developed award-winning, cutting-edge technology to transform the way hospitals interact with patient information.

Colleen Cline has over 33 years’ experience in the financial services and insurance industries, including sales, marketing, business development and management. She worked with Fifth Third Bancorp and Allstate Insurance, receiving various industry awards in sales, marketing and customer satisfaction. She is also an entrepreneur and top performer in the health care and wellness industry.

Moon Equity Holdings Corp. (OTC: MONI), closed Thursday's trading session at $0.0658, up 1.2308%, on 1,280,657 volume with 73 trades. The average volume for the last 3 months is 1.281M and the stock's 52-week low/high is $0.0008/$0.14654.

Recent News

StraightUp Resources Inc. (CSE: ST)

The QualityStocks Daily Newsletter would like to spotlight StraightUp Resources Inc. (CSE: ST).

StraightUp Resources (CSE: ST) recently announced the completion of a high-resolution Heli-borne magnetic survey (“MAG”) on the RLX North and RLX South properties (“RLX Properties”) that comprise the company’s largest area of operation currently. According to Mark Brezer, the company’s president and CEO, the projects are in the heart of the Red Lake Mining District, an area that is seeing a resurgence of gold-bearing deposits that were overlooked in the past. To view the full article, visit https://ibn.fm/kdDxl

StraightUp Resources Inc. (CSE: ST) is a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America. The company’s flagship properties are located in the Red Lake Mining District of Ontario, Canada, renowned for over 30 million ounces of historic gold production. Other key projects extend into the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. The company’s management team is led by dedicated professionals, aiming to maximize shareholder value while employing modern exploration techniques and principles to achieve its goals.

The mission of StraightUp Resources is to maximize shareholder wealth through mineral discoveries at projects with robust potential, maintain long-lasting partnerships, and continue to focus on the acquisition, development and exploration of mineral resource properties in North America. The company’s objective is to continue to locate and develop economic, precious and base metal properties of merit.

The company’s 10,000-hectare (almost 25,000 acres) RLX Projects are contiguous to various Evolution Mining, Great Bear Resources, Pacton Gold and Dixie Gold properties. Its 2,000-hectare (just under 5,000 acres) Belanger Project is contiguous to Infinite Ore’s Fredart and Garnet/Arrow properties. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and Ferdinand Gold properties located in the Red Lake District, a location touted as having one of the best metal-endowed greenstone belts in the world. The Bear Head Gold Project is located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp and 14 km northeast of the former gold mine, Golden Patricia. It amassed 620,000 ounces of gold at an average of 15.2 g/t Au from 1988-1997. The property is bordered by an Australian miner massive gold project. Known gold occurrences are already mapped on the Bear Head property, as are previous drill holes and results. Once the data is re-examined, an exploration budget and subsequent plans will be announced by the company.

Projects

Ontario’s Red Lake Mining District is one of Canada’s most prolific gold mining districts, renowned for its high-grade gold deposits. This is a mining-friendly, politically stable jurisdiction with a skilled labor force and infrastructure specifically built around meeting the needs of the mining industry.

RLX North & South Projects
At over 10,000 hectares, the RLX North and RLX South Projects represent a district-scale exploration opportunity. The RLX North and RLX South Projects are well positioned on-strike to the southeast of the district’s largest gold deposit (Red Lake Gold Mines – Evolution Mining). The project is adjacent to Great Bear Resources’ Sobel Project. Great Bear Resources is also in the process of evaluating the area for significant regional-scale structural controls and has proposed additional work on its neighboring project in the near term. These properties are highly accessible, with the southern boundary only eight kilometers from the paved highway into Red Lake, and can be accessed by forest service roads which traverse throughout the properties.

Belanger Project
Historic exploration work on the 2,000-hectare property has identified three significant surface exposures of gold, copper and silver. Early exploration work will focus on validating historic sampling results and following the occurrences along strike with a view to better understanding the nature and controls on mineralization. The property has excellent forest road access from the town of Ear Falls.

Ferdinand Gold Project
The Ferdinand property is situated within the southeastern extension of the Confederation-Uchi greenstone belt, one of the most metal-endowed greenstone belts in the world by square kilometer. It consists of 17 contiguous mining claims covering approximately 7,143 hectares (17,650 acres), located 13 kilometers northwest of the town of Slate Falls. Access is currently by logging roads, with forestry logging operations scheduled for expansion on the property. StraightUp recently completed a heliborne magnetic survey consisting of 1,994 line-km at 50m line spacings covering the entire property. The MAG survey was designed to provide geological and structural details of a 25km long southeast extension of the Confederation-Uchi greenstone belt along the Fry-Bamaji Deformation Zone.

Bear Head Gold Project
The Bear Head Gold Project comprises 31 mining claims totaling 1,944 hectares (4,800 acres) in the Meen-Dempster Greenstone Belt of the Uchi Subprovince, host to the Golden Patricia former gold mine, which produced 620,000 ounces of gold from 1988 to 1997. The Dorothy Main gold deposit owned by Ardiden lies only one kilometer from the Bear Head Gold Project. The Dorothy Main gold deposit holds noncompliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. The company looks forward to adding the Bear Head Gold Project to its exploration efforts, with a work program to be conducted later in the fall of 2021.

Management Team

Mark Brezer is CEO, President, and Director of StraightUp Resources Inc. He is a successful businessman and holds a Geography/Geology degree from the University of Arizona. He has worked as a Project Manager and has overseen quality control, environmental monitoring and safety programs related to road construction. He has also held roles in media relations and marketing. He has been actively involved in the research and investment of junior mining companies for over 25 years. Time in the field and personal interest led him into extensive first aid training, and he is certified as a paramedic and firefighter.

Daniel Cruz is CFO and Director at StraightUp Resources. He is an experienced financial industry professional, having worked for 12 years as a senior investment advisor at Canadian broker-dealers, where he gained experience in equity research, asset management, investor relations, corporate finance and venture capital. He was one of the youngest Senior Investment Advisors at Canaccord Financial Inc. in 2010. He is also the co-founder and current director of Liquid Media Group Inc., a Nasdaq-listed issuer. During his tenure as CFO, he helped that company list on Nasdaq and raise over $20 million.

Matthew Coltura is a Director at StraightUp Resources. He has a Bachelor of Business Administration from Okanagan College, where he specialized in finance. He has worked in the finance industry for more than three years. Currently, Mr. Coltura is the CFO of Cayenne Capital Corp. He was also a director of PreveCeutical Medical Inc. from July 2016 to September 2019, a director of Sproutly Canada Inc. (formerly Stoneridge Exploration Corp.) from March 2015 to July 2018, and, since March 2018, has worked as a financial specialist at Quip Finance.

StraightUp Resources Inc. (CSE: ST), closed Thursday's trading session at $1.95, even for the day, on 3,600 volume with 2 trades. The average volume for the last 3 months is 44,439 and the stock's 52-week low/high is $0.13/$0.35.

Recent News

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR) .

  • Reported quarterly revenue of $5.39 million (includes SMS & MMS, Telecommunications Products & Services businesses, and Big Data);
  • Reported quarterly growth in SMS & MMS business revenue of $0.73 million or 25% compared to Q2 2021;
  • Reported quarterly growth in Telecommunications Products & Services business revenue of $1.0 million or 142% compared to Q2 2021;
  • Reported revenues of $32,702 in Big Data;
  • Reported quarterly cost of revenue of $4.69 million which was an increase of $1.33 million or 39% compared to Q2 2021;
  • Reported quarterly net loss of $1,454,617 which was an increase of $0.49 million or 51% compared to Q2 2021;
  • Basic and Diluted loss per share of $0.04;
  • At August 31, 2021, FingerMotion had $878,085 in cash, a working capital surplus of $5,037,533, and a positive shareholders' equity of $5,228,987;
  • Total Assets were $9.38 million, Total Current Liabilities were $4.15 million and Total Liabilities were $4.15 million; and
  • 42,201,260 common shares were issued and outstanding as of August 31, 2021.

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday's trading session at $5.83, off by 1.0187%, on 7,787 volume with 31 trades. The average volume for the last 3 months is 7,787 and the stock's 52-week low/high is $3.22/$17.00.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

  • Tingo announces partnership with MELD, a DeFi non-custodial banking protocol for secure lending and borrowing of crypto and fiat currencies
  • Two companies share common commitment to bring financial freedom and inclusion to people
  • Tingo aims to encourage the $2 trillion-dollar crypto-economy to invest in African farmers; partnership intends to explore DeFi solutions such as decentralized low-interest loans

Tingo International Holdings, a majority shareholder of Tingo (OTCQB: IWBB), a unique Africa-focused Agri-Fintech company, announces a new partnership with MELD in a bid to bring a highly efficient decentralized finance (“DeFi”) lending and borrowing protocol to customers in Africa (https://ccw.fm/TgAij). Tingo (OTCQB: IWBB) is Nigeria’s leading agri-fintech and device-as-a-service company with over $600 million in annual revenues and nearly 10 million subscribers. Created in 2001 by Dozy Mmobuosi, company CEO and cofounder, as an ecosystem to support the largely unbanked agricultural sector in Nigeria, Tingo designed the country’s first SMS mobile banking and payment platform, which is still in use today. Tingo has since evolved into a rapidly expanding group of fintech, agritech, mobile and technology companies. To view the full article, visit https://ibn.fm/t0aAB

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Thursday's trading session at $1.7, off by 5.5556%, on 810 volume with 5 trades. The average volume for the last 3 months is 810 and the stock's 52-week low/high is $1.01/$8.98.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Similar to the cannabis industry, the CBD industry is growing at a rapid rate, with forecasts showing that in less than a decade, the market will have a value in the billions. CBD, or cannabidiol in full, is produced by extracting oils from hemp. It has different uses and is becoming popular as an alternative treatment to various health challenges. Researchers from Virginia Tech may have found a new use for these nonpsychoactive hemp oils: making plywood stronger. Firms such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) making CBD products could soon have an avenue to use the wastes generated from CBD extraction processes.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Thursday's trading session at $0.6633, off by 2.5419%, on 92,703 volume with 80 trades. The average volume for the last 3 months is 92,703 and the stock's 52-week low/high is $0.3933/$1.65.

Recent News

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced two new partnerships between Ketamine Wellness Centers LLC (“KWC”) and the Veterans Administration (“VA”) Community Care Networks of Illinois and Minnesota . According to the update, the nation's largest chain of psychedelic wellness clinics, KWC, will offer ketamine treatments to veterans at no out-of-pocket cost at their locations in Naperville, Illinois, and Burnsville, Minnesota. To view the full press release, visit https://ibn.fm/8pYp3. During a recent Congressional hearing, Rep. Colin Allred revealed that the Department of Veterans Affairs (“VA”) has closely been following studies on the therapeutic benefits of psychedelic substances such as MDMA for veterans. The meeting, which was held last month before the House Veterans’ Affairs Committee, focused on innovative approaches to deal with suicide prevention in veterans. Meanwhile, clinics administering ketamine treatments already exist in some U.S. jurisdictions while companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) operate extensive networks of such clinics in Canada.

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Inc. (DELCF), closed Thursday's trading session at $0.1915, off by 0.931195%, on 251,363 volume with 108 trades. The average volume for the last 3 months is 251,363 and the stock's 52-week low/high is $0.17/$1.038.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (NASDAQ: DRIO).

DarioHealth (NASDAQ: DRIO), a leader in the global digital-therapeutics (“DTx”) market, today announced its entry into an agreement with one of the largest U.S. national health plans to offer its self-insured employer customers the Dario digital behavioral health solution as part of its behavioral health offering.  According to the update, initial members are expected on the platform in the fourth fiscal quarter of 2021, with additional rollout anticipated over the course of 2022. To view the full press release, visit https://ibn.fm/1wO29

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Thursday's trading session at $16.2, up 20.178%, on 774,960 volume with 7,675 trades. The average volume for the last 3 months is 774,960 and the stock's 52-week low/high is $10.01/$31.85.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of a phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety (“AjDA”). In parallel with advancing its ongoing PALISADE phase 3 clinical program for PH94B in the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), VistaGen plans to explore PH94B’s potential in additional anxiety disorders through a series of small phase 2A trials, the first of which is in AjDA. To view the full press release, visit https://ibn.fm/fGyZc

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Thursday's trading session at $2.5, up 0.401606%, on 619,998 volume with 2,969 trades. The average volume for the last 3 months is 619,998 and the stock's 52-week low/high is $0.6088/$3.55.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) today announced that a seven-day reconnaissance mapping, prospecting and sampling program has been completed at the company's Smoke Mountain Property located in the Central British Columbia porphyry/polymetallic belt. The project is strategically located adjacent to Surge Copper's claims located 15 km northeast of Berg and 23 km north of the Imperial Metals Huckleberry project. To view the full press release, visit https://ibn.fm/MaTpm

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Thursday's trading session at $0.44, up 6.2161%, on 266,422 volume with 51 trades. The average volume for the last 3 months is 266,422 and the stock's 52-week low/high is $0.21/$0.87.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading